Asuragen Signs Agreement with Biogen Idec to Pursue Companion Diagnostic Strategy
“The integrated drug-diagnostic co-development strategy being pursued by Biogen Idec and Asuragen has enormous potential to help physicians identify patients that will benefit from specific cancer treatments, and will be another step towards delivering on the promise of personalized medicine,” said Matt Winkler, CEO of Asuragen. “We look forward to leveraging our long history and broad expertise in biomarker discovery, pharmacogenomic services, and diagnostic development capabilities for this project.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.